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Dear Colleague: 
 
As you should already be aware, Dr. Ken Castro, Director, Division of Tuberculosis 
Elimination (DTBE), has accepted a request from the leadership of the National Center 
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) to serve as Acting 
Director of the Division of HIV/AIDS Prevention (DHAP), until a permanent Director for 
DHAP is found. This is the result of Dr. Jonathan Mermin, former Director of DHAP, 
being selected as the new Director of NCHHSTP. Dr. Castro agreed to work in this 
capacity on a time-limited basis, and started on August 19. In addition, Phil Talboy, 
DTBE Deputy Director, is on a temporary detail to the Field Services Office, Office of 
State, Tribal, Local, and Territorial Support (OSTLTS), until January 2014 to help DTBE 
and other divisions in NCHHSTP re-build the crucial Public Health Advisor pipeline of 
the future. In the interim, I have agreed to serve as Acting Director, DTBE. While I am 
serving in this capacity, Dr. John Jereb, Field Services and Evaluation Branch (FSEB) 
medical officer, has agreed to serve as the DTBE Acting Associate Director for Science. 
Kathryn Koski is serving as Acting Deputy Director, and Lee Ann Ramsey is serving as 
Acting Associate Director for Management and Operations, DTBE. Dr. Castro and I both 
appreciate your support of these individuals as they carry out these important duties. 
 
In April 2013, DTBE issued a notification via the CDC Health Alert Network (HAN) 
regarding nationwide shortages of Tubersol and Aplisol, the only U.S. Food and Drug 
Administration–approved purified protein derivative (PPD) solutions for use in 
performing tuberculin skin tests (TSTs). In September 2013, DTBE issued an updated 
health alert. This stated that “although supplies were restored in early June 2013, 
Tubersol is in shortage again until at least the middle of October 2013. At the current 
time, the 5 tuberculin unit/0.1 mL, 5 mL (50-test) multiple dose vials are unavailable. 
The 5 tuberculin unit/0.1 mL, 1 mL (10-test) multiple dose vials are in limited supply.” 
 
CDC recommends any of three general approaches for addressing the shortages of 
tuberculin skin test antigens: 
1. Substitute IGRA blood tests for TSTs.  
2. Substitute APLISOL for TUBERSOL for skin testing if APLISOL is available. 
3. Allocate TSTs to priority usages, such as TB contact investigations, as determined by 
public health authorities. 
 
Some surveillance programs for TB infection control rely on routine serial TSTs. 
Switching products or methods might make serial changes in test results difficult to 
interpret. The apparent conversions of results from negative to positive or reversions 
from positive to negative could be caused by inherent inter-product or inter-method 
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discordance. In settings with a low likelihood of TB exposure, the deferment of routine 
serial testing should be considered in consultation with public health and occupational 
health authorities. 
 
Please see the official health update at http://emergency.cdc.gov/HAN/han00355.asp 
for further details and discussion of the recommendations above. 
 
Updates about the shortages of tuberculin skin test solutions are posted by the FDA 
Center for Biologics Evaluation and Research at 
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/ucm351921.ht
m. 
 
As one additional update, Sanofi Pasteur reports that the supply of Tubersol has 
improved and will steadily improve for the remainder of the year. Existing Sanofi 
Pasteur customers can purchase directly from Sanofi Pasteur by visiting 
VaccineShoppe.com® or by calling 1-800-VACCINE (1-800-822-2463). In addition, 
limited quantities of Tubersol Diagnostic Antigen are available through the wholesaler/ 
distributer channel. Customers who normally order through this channel should work 
with their preferred wholesaler/distributor to better understand Tubersol Diagnostic 
Antigen quantities that may be available to them. If you are a new customer or have 
inquiries regarding the availability of Tubersol Diagnostic Antigen, you should contact 
Sanofi Pasteur at 1-800-VACCINE (1-800-822-2463), or your wholesaler/distributor. 
 
On July 19, a number of DTBE staff members were recognized at the NCHHSTP Honor 
Awards Ceremony. Please see the article in this issue about the awards won by our 
staff for their important work. 
 
 
 
 
      Philip LoBue, MD, FACP, FCCP  
Acting Director 
Division of Tuberculosis Elimination  
National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention 
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HIGHLIGHTS FROM STATE AND 
LOCAL PROGRAMS 
 
San Antonio’s TB Chest Clinic Hosts 
Eastern European Medical 
Professionals 
 
 
On January 11, 2013, San Antonio Metro Health 
TB staff hosted several medical professional 
visitors from Eastern Europe. The visitors were in 
town as guests of the Heartland National TB 
Training Center. Representatives were from the 
countries of Moldova, Georgia, and Ukraine. Also 
present was a CDC representative who is 
working with these countries to address their TB 
challenges, Dr. Patrick Moonan of DTBE. These 
medical professionals visited with Metro Health’s 
TB staff to learn more about how our TB staff 
perform contact investigations, conduct 
surveillance, and use directly observed therapy 
for patient care as well as for managing latent TB 
infections. The group had a Russian language 
interpreter who facilitated the discussion, which 
lasted several hours. 
 
Eastern Europe has significant challenges with 
drug-resistant TB. In the past, countries of this 
region have not investigated potential exposures 
and treated asymptomatic patients with drugs to 
prevent future progression to disease. CDC is 
partnering with officials of these Eastern 
European countries to develop a study to 
enhance the contact investigation, diagnosis, and 
treatment of exposed persons. It is expected that 
these improvements will lead to less exportation 
of TB and drug resistance through immigration, 
and hopefully will reduce the overall disease 
burden experienced in these countries from this 
devastating disease. 
 
—Reported by Carlos Alcantara 
CDC PHA, San Antonio Metropolitan Health District 
 
 
DTBE Winners of 2013 
NCHHSTP Honor Awards 
 
On Friday, July 19, 2013, CDC’s NCHHSTP 
recognized the employees in its divisions for their 
valuable contributions. DTBE was well 
represented at the ceremony. Following are the 
DTBE recipients of these awards. (Please note: 
in several categories, the recipients included staff 
of other divisions as well; we have only included 
DTBE staff). 
 
TB 
Notes 
Centers for Disease Control and Prevention 
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Division of Tuberculosis Elimination ♦ 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
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Excellence in Frontline Public Health Service - 
Domestic  
Donato Ruggiero  
 
For exemplary leadership to DTBE by filling 
multiple significant gaps during numerous staff 
reductions. 
 
Excellence in Laboratory Research  
Laboratory Branch and CDC Global Laboratory 
Activity  
Lauren Cowan  
Lois Diem  
Denise Hartline  
Dorothy Kaminski  
Kim McCarthy  
Beverly Metchock  
Glenn Morlock  
Bonnie Plikaytis  
Jamie Posey  
David Sikes  
David Temporado  
Sean Toney 
For traveling to domestic and international 
laboratories affiliated with the Tuberculosis Trials 
Consortium sites, assessing procedures, and 
sharing knowledge and expertise to strengthen 
public health research collaboration. 
 
Excellence in Program Delivery  
NCHHSTP U.S.-Affiliated Pacific Islands 
Workgroup 
Alstead Forbes  
Andrew Heetderks  
Angela Starks  
For exemplary leadership and support to the 
U.S.-affiliated Pacific Islands through Program 
Collaboration and Service Integration.  
 
Excellence in Public Health Protection Award  
Sundari Mase 
In the face of repeat shortages and other 
problems that hinder access to second-line drugs 
(SLD), Dr. Mase has led the medical operations 
team in DTBE in responding to the SLD 
shortages. 
 
CDC Director’s Award for Efficiency  
TB Outbreak Response Group 
Sandy Althomsons  
Lori Armstrong  
Christopher Etchells  
Tracie Gardner  
Juliana Grant  
Anne Marie France  
Maryam Haddad  
Carla Jeffries  
Lauren Lambert  
Lilia Manangan  
Kiren Mitruka 
Sapna Morris  
Melissa Pagoa 
Krista Powell  
Courtney Yuen 
For collaborative spirit and creation of an efficient 
outbreak response workforce.  
 
Excellence in Human Capital Management – 
Employee Development (James Virgil Peavy 
Award)  
TB Notes is a quarterly publication of the Division 
of TB Elimination (DTBE) of the National Center 
for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention (NCHHSTP), Centers for Disease 
Control and Prevention (CDC). This material is in 
the public domain, and duplication is encouraged. 
For information, contact 
TB Notes Editor 
CDC/NCHHSTP/DTBE, Mailstop E10 
1600 Clifton Road, NE 
Atlanta, GA  30333 
Fax: (404) 639-8960 
 
DIRECTOR, DTBE 
Kenneth G. Castro, MD 
 
EDITORIAL REVIEW BOARD 
Ann Lanner, Managing Editor 
Sandy Althomsons, MA, MHS 
Beverly DeVoe-Payton 
Michael Fraser 
Philip LoBue, MD, FACP, FCCP 
Kawi Mailutha 
Mary Naughton, MD, MPH 
Frances Tyrrell, MPH, MT (ASCP), SM 
 
Visit DTBE’s Internet home page, 
http://www.cdc.gov/tb, 
for other publications, information, and 
resources available from DTBE. 
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NCHHSTP Workforce Development Champions 
Workgroup 
Kathryn Koski  
Linda Leary  
For exceptional leadership and innovation in 
developing key workforce development and 
work-life balance initiatives. 
 
Excellence in Information Technology  
NCHHSTP ATLAS Steering Committee 
Carla Jeffries  
For exemplary leadership and innovation of 
NCHHSTP’s Atlas through Program 
Collaboration & Service Integration.  
 
Excellence in Volunteer Service Award  
Lee Ann Ramsey 
For exemplary leadership and support of 
inclusion-based Girl Scouting. 
 
CDC Director’s Award for Efficiency  
NCHHSTP Policy Award for Center and Division 
Policy Leadership 
Ann Cronin  
For exemplary critical thinking and thoughtful 
analyses, vital to the successful implementation 
of NCHHSTP’s programs.  
 
 
Healthy People 2020 Progress 
Review 
 
The Burden of TB and Infectious 
Diseases in the U.S. and Abroad 
 
Overview 
On July 30, 2013, Dr. Kenneth Castro, Director, 
DTBE, joined other public health leaders in a 
Healthy People 2020 progress review. This 
Healthy People progress review included, for the 
first time, a presentation by a nonfederal partner, 
Ed Zuroweste, MD, Chief Medical Officer, 
Migrant Clinicians’ Network. Howard Koh, MD, 
Department of Health and Human Services 
(HHS) Assistant Secretary for Health, served as 
moderator. Other participants included Irma 
Arispe, PhD, Associate Director, National Center 
for Health Statistics (NCHS); Tom Kenyon, MD, 
Director, CDC’s Center for Global Health (CGH); 
and Craig Shapiro, MD, HHS Director, Office of 
the Americas, Office of Global Affairs (OGA). The 
review was conducted in Washington, DC, as a 
webinar, and had an estimated audience of 500 
viewers. An underlying theme throughout the 
progress review was our need to continue to 
align domestic elimination efforts with the global 
fight against TB.   
 
What Is Healthy People? 
Healthy People is a collaborative U.S. initiative 
that provides science-based, 10-year national 
objectives for promoting health and preventing 
disease, to improve the health of all Americans. 
The project is managed overall by the HHS 
Office of Disease Prevention and Health 
Promotion (ODPHP). It consists of goals and 
objectives, with targets that are designed to 
guide national health promotion and disease 
prevention efforts. Healthy People 2020, the 
current version of this ongoing effort, covers 42 
topic areas, and includes 1,200 objectives or 
measures. 
 
Data Overview: National Center for Health 
Statistics 
Dr. Irma Arispe (NCHS) reported that in an 
earlier era, TB was a leading cause of death—
not just in other parts of the world, but in the 
United States as well. In 1900, TB was the 
second leading cause of death in this country. As 
recently as 1950, it was the seventh leading 
cause of death. Today we have pushed TB off 
the list of leading causes of death in this country. 
However, TB remains a serious challenge to 
global health. Worldwide, it is the leading cause 
of death among persons with HIV. It is also the 
second leading cause of death from a single 
infectious agent. 
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Global Leading Causes of Death, 2008 
Dr. Arispe summarized her key points as follows: 
overall, U.S. TB rates are decreasing. However, 
disparities persist for racial and ethnic minorities 
and those born outside the United States. In 
addition, TB remains an urgent public health 
problem in Asia and Africa. Health issues abroad 
can directly impact health in the United States.  
 
Tuberculosis: Domestic Overview 
Speaking next, Dr. Castro described DTBE as 
the equivalent of the National TB Program for the 
United States. DTBE funds state and local TB 
programs, as well as two consortia that carry out 
program-relevant research: the TB Trials 
Consortium (TBTC) and the TB Epidemiologic 
Studies Consortium (TBESC). CDC also provides 
technical assistance in 22 countries, in 
partnership with the U.S. Agency for International 
Development (USAID), the World Health 
Organization (WHO), and others.  
 
To explain recent trends, Dr. Castro discussed 
the 1985–1992 U.S. resurgence of TB following 
decades of decline. The causes: first, the 
dismantling of TB clinical services after funding 
disappeared in the late 1970s and early 1980s. 
Other causes included the emerging HIV 
epidemic, immigration from countries where TB 
was common, spread of TB in institutions, and 
emergence of multidrug-resistant (MDR) TB. 
 
Excess TB Cases, U.S. 1985–1992  
The resurgence, which caused an estimated 
52,100 excess TB cases, prompted action. New 
resources were made available, and funds were 
quickly mobilized. These were used to hire staff 
and to focus on training and education. The 
funding increases also allowed the U.S. to 
improve the detection of TB cases, upgrade state 
laboratories for early diagnosis and recognition of 
drug resistance, update treatment and infection 
control recommendations, pay for the broad-
scale use of directly observed therapy, and 
emphasize the need for ongoing program 
evaluation. 
 
These steps paid off, and TB began decreasing 
in both U.S.-born and foreign-born persons in the 
United States. The decreases in TB in U.S.-born 
persons have been substantive. However, in 
comparison, TB decreases for the foreign-born 
persons have been so modest as to remain 
relatively stable; thus, the proportion of U.S. TB 
cases that they account for rose from 28% in 
1991 to 62% by 2011. Rates in 2011 were nearly 
12 times higher for foreign-born persons than for 
U.S.-born persons and were still above the 
Healthy People 2020 target of 14.0 per 100,000 
population. 
 
TB: Global Overview 
Based on this changing epidemiology, the 
Institute of Medicine2 urged the U.S. to become 
directly engaged in the global fight against TB. 
CDC and other U.S. agencies now collaborate 
closely with many international partners in this 
JAMA 1994; 272: 536. 
NUMBER 3, 2013 
8 
 
global effort. Global TB control work here at CDC 
spans three Centers and four divisions; yet, it is 
highly collaborative and synergistic. 
 
Investment Upfront Leads to Big Dividends 
for TB Control  
 
Moreover, there is potential for enormous return 
on investment in TB control programs in 
countries from which most of our foreign-born TB 
patients originate. Dr. Castro shared the example 
that an investment in screening U.S.-bound 
immigrants and implementing directly observed 
therapy, short-course (DOTS) in Mexico could 
result in remarkable reductions in TB incidence 
among this population. A $35 million U.S. 
investment in Mexico’s TB program would result 
in fewer cases of TB in the United States, fewer 
deaths from the disease, and net discounted 
savings of $108 million over 20 years. 
 
Dr. Castro’s key takeaway messages were as 
follows: there remain many challenges to U.S. 
elimination of TB. Funding gaps are again 
leading to inadequate human resources, limited 
access to diagnosis and treatment services, and 
limited surveillance to document burden and 
impact. Combating TB among foreign-born 
persons will remain the key to any progress 
toward elimination. MDR TB and HIV-associated 
TB, here and abroad, pose a threat to our ability 
to fight this disease. The complacency that 
comes with a successful program may ironically 
lead to the disinvestment in these programs, loss 
of clinical expertise and of capacity to respond to 
outbreaks, and concentration of the epidemic in 
the most vulnerable groups.  
 
Yet there is good news: the trend of decreasing 
U.S. TB incidence as a result of concerted efforts 
provides a remarkable success story: cases have 
declined more than 60.5% from the 1992 peak. 
However, as with many other communicable 
diseases, TB prevention and control requires 
building the best international partnerships to 
help meet domestic needs. Recent research 
developments are yielding results that are being 
translated into program improvements. 
 
Overview: Center for Global Health 
Viewers next heard from Dr. Tom Kenyon (CGH). 
His key points were that there is a continuing 
need to strengthen public health systems 
worldwide and assure global health security. 
Efforts to address global TB control are 
underway, but they need to be enhanced—
including providing technical support, 
strengthening surveillance and laboratory 
systems, building in-country capacity, and 
contributing to the evidence base for 
implementation of effective TB control strategies. 
He stated that TB elimination in the United States 
is not possible without addressing TB among 
foreign-born persons—both in their country of 
origin and here. Continued U.S. investment in TB 
control in other countries saves lives, protects 
Americans at home and abroad, and makes 
economic sense. 
 
U.S.-Mexico Border Region Issues 
Dr. Craig Shapiro followed with a talk about TB in 
the U.S.-Mexico border region. His key points 
were that TB rates are higher in the U.S.-Mexico 
border region than in other areas of United 
States. Major challenges in the area include 
continuity of care and harmonizing treatment 
protocols across state and national lines. Efforts 
of the U.S.-Mexico Border Health Commission 
are aimed at promoting binational collaboration 
(federal, state, and local levels) and cross-border 
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sharing of information and resources for 
prevention and treatment. 
 
Migrant Clinicians Network: Case Study 
Dr. Ed Zuroweste reported on the Migrant 
Clinicians Network, whose physicians provide 
care for migrants and foreign-born workers in the 
Unites States. He gave an example of a 
complicated but ultimately successful case 
involving a migrant who traveled extensively 
across the U.S. but eventually completed 
treatment for TB. 
 
—Reported by Carla Jeffries, JD, MPH 
and Ann Lanner 
Div of TB Elimination 
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Blast from the Past -- TB Today! 1990 
 
While going through old files in preparation for 
DTBE’s move to building 12 here at Corporate 
Square, Dr. Wanda Walton, Chief, 
Communications, Education, and Behavioral 
Studies Branch, found this photo (see next page) 
of participants from the November 26–30, 1990, 
TB Today! class. Do you recognize anyone in the 
photo? Names of participants are listed below 
alphabetically. A few are missing from the photo. 
—Reported by Wanda Walton, PhD, 
and Ann Lanner 
Div of TB Elimination 
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Suzanne A. Banda 
Linda S. Barnett 
Cheryl L. Baughman 
Lesley-Anne T. Behan 
Elaine C. Benjamin 
Stanley R. Bissell 
Rosa Black 
Sheryl V. Butler 
Hilda Castillo 
Anita Chesney 
William L. Coggin 
Beverly E. DeVoe 
Rosamond R. Dewart 
Marie S. Dorsinville 
Sheryl A. Gonzalez 
 
Lon S. Gross 
Mary Ann Hawley 
Bonnie L. Jameson 
John A. Jereb 
Marion S. Johnson 
Katherine A. McLeod 
Michael F. Kelley 
Ken K. Komatsu 
James E. Lynch 
Kathleen M. Martin 
Stephen S. Martin 
Ann D. McBride 
Robyn McDermott 
Phyllis C. McGuire 
 
Kathleen S. Moser 
Barbara A. Mullin 
Donald G. Myers 
Edwin A. Paz 
Linda J. Perry 
Edwin M. Rodriguez 
Kathleen E. Russell 
Dorothy M. Schadl 
Stephanie M. Steinbart 
Vicky S. Stevens 
Michelle C. Thomas 
Vic Tomlinson 
Dawn M. Tuckey 
Gary E. Voccio 
Victoria Webb 
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Hot Off the Press! Quality Assurance 
for Tuberculosis Surveillance Data: A 
Guide and 
Toolkit – 2013 
Background 
Quality assurance 
(QA) is a critical part 
of any successful 
surveillance system. 
QA is a continuous 
cycle of monitoring, 
evaluating, and 
improving data 
quality.   
The National 
Tuberculosis Surveillance System (NTSS), 
located in the Division of Tuberculosis 
Elimination (DTBE), CDC, is the national 
repository of tuberculosis (TB) disease 
surveillance data in the United States. CDC 
receives data on TB cases from reporting 
jurisdictions through a standardized data 
collection form, the Report of Verified Case of 
Tuberculosis (RVCT).  
The RVCT is revised periodically as the 
epidemiology of TB in the United States changes. 
The most recent revision was implemented in 
2009. As part of that revision, data collection and 
reporting transitioned into web-based systems. 
An interdisciplinary DTBE team collaborated with 
key national partners, state public health officials, 
and other local healthcare professionals to 
develop and launch a national training program 
on the new RVCT. As a logical follow-up to the 
RVCT trainings, the DTBE staff began working 
individually with state public health partners to 
develop the QA guide and toolkit. 
DTBE wants to ensure that data are collected as 
uniformly as possible across all jurisdictions, 
whether large or small. The RVCT QA training 
team, in collaboration with key partners, 
developed the QA guide and toolkit to provide 
standardized methodologies, skill development, 
and tools to enhance the capacity for QA. The 
team used the systematic health education 
approach to develop training materials: this 
included needs assessment, development, pilot 
testing, implementation, and outcome evaluation. 
How to Access the Materials 
A limited number of copies of the QA Guide and 
Toolkit have been printed. Each reporting 
jurisdiction will receive at least one hard copy 
with a CD that includes the toolkit.   
To view or download the “Quality Assurance for 
Tuberculosis Surveillance Data: A Guide and 
Toolkit,” please visit the CDC website or the 
RVCT ftp site listed below.  
• http://www.cdc.gov/tb/programs/rvct/default.h
tm (Available late fall 2013) 
• ftp://ftp.cdc.gov/pub/Software/TIMS/2009 
RVCT Documentation/RVCT Training 
Materials/ 
(Note the spaces in the FTP URL) 
Quality Assurance Components 
The QA process is based on the 2014 CDC 
Tuberculosis Elimination and Laboratory 
cooperative agreement and the results of a QA 
needs assessment conducted with 11 of the 60 
reporting jurisdictions. The process includes five 
components as shown in the figure below.  
Five Quality Assurance Components for TB 
Surveillance Data 
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QA Components 
QA 
Components 
Definition 
Case Detection Detection of one instance of a 
specific disease or exposure, 
e.g., TB. A front-line surveillance 
activity, it is typically 
accomplished as a by-product of 
routine medical or veterinary 
care, or laboratory work, or via 
an astute observer such as a 
health care worker. 
Data Accuracy The data submitted match patient 
records maintained at the point of 
care. The recorded data in the 
surveillance system are 
consistent with what activities 
happened in a clinical encounter, 
whether or not they were 
clinically appropriate. 
Data 
Completeness 
A measure that indicates whether 
the information submitted 
contains the complete set of data 
items. 
Data Timeliness Prompt reporting of surveillance 
data to health authorities. 
Data Security 
and 
Confidentiality 
Data security is the protection of 
public health data and 
information systems to prevent 
unauthorized release of 
identifying information and 
accidental loss of data or 
damage to the systems. 
Data confidentiality is the 
protection of personal information 
collected by public health 
organizations. The right to such 
protection is based on the 
principle that personal 
information should not be 
released without the consent of 
the person involved except as 
necessary to protect public 
health. 
Goal 
The goal for the QA manual is to help improve 
the quality of TB surveillance data by providing 
TB surveillance reporting jurisdictions with 
• A standardized process for QA, and  
• Tools that can be used and adapted for QA. 
Objectives  
After using this guide and toolkit, the user should 
be able to 
• Describe the five components of the QA 
process, 
• Access various QA tools for TB surveillance 
data, and 
• Describe what to include in a written QA 
protocol as required by the cooperative 
agreement. 
 
 
 
 
About the Guide 
• The guide includes a set of nine chapters 
and four appendices. A description of the 
chapters and appendices is shown in the 
table below.  
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Description of Chapters and Appendices 
 
Chap. Title Description 
1 Introduction to 
the Guide and 
Toolkit 
Background, goals and 
objectives, target 
audience, and how to 
use the guide and toolkit   
2 National TB 
Surveillance 
System Data 
Flow 
Data flow structure from 
the jurisdictions to CDC 
3 Overview of the 
QA Process 
Definition of QA, factors 
influencing data quality, 
cooperative agreement, 
QA component 
definitions, and tools 
QA components that provide the main content 
4 Case Detection Purpose, definitions, 
process, and tools 
5 Data Accuracy Purpose, definitions, 
process, NTSS data 
validation, laboratory 
data accuracy, data 
validation pilot project, 
and tools 
6 Data 
Completeness 
Purpose, definitions, 
process, missing and 
unknown, data 
completeness, accuracy 
study, and tools 
7 Data Timeliness Purpose, definitions, 
process, case count 
process, and tools 
8 Data Security 
and 
Confidentiality 
Purpose, definitions, 
process, data security 
and confidentiality 
guidelines, and tools 
Chap. Title Description 
9 Quality 
Assurance 
Cross-cutting 
Systems and 
Process: NTIP, 
TB GIMS, and 
Cohort Review  
Examples of systems 
and a process that can 
be used for improving at 
least three of the five QA 
components (e.g., 
accuracy, completeness, 
and timeliness). These 
include the National TB 
Indicators Project, the 
TB Genotyping 
Information 
Management System, 
and cohort review.  
10 Toolkit for 
Quality 
Assurance 
Examples of the tools 
that can be easily 
adapted for local use. 
Tools are grouped by 
chapter and content 
topic (e.g., Chapter 3: 
Overview of the Quality 
Assurance Process). 
App. Title Description 
A References List of all references 
used in the development 
of this guide 
B Glossary Compilation of all the 
definitions provided in 
this guide 
C Quality 
Assurance 
Process Slides 
Set of slides that 
describe the QA process 
D Report of 
Verified Case of 
Tuberculosis 
(RVCT) 
Questions and 
Clarifications 
Compilation of questions 
and clarifications since 
the 2009 publication of 
the RVCT instructions. 
Updated periodically and 
is available at 
http://www.cdc.gov/tb/pr
ograms/rvct/default.htm. 
E Answers to the 
Exercises 
Discussions of answers 
to exercises included in 
this guide 
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About the Toolkit  
Staff from CDC and various jurisdictions 
developed approximately 50 QA tools that 
include tables, charts, graphs, processes, and 
templates. The tools are available in commonly 
used software so that they can be easily used or 
adapted to a jurisdiction’s setting.  
Additional Information  
For additional information about QA for 
Tuberculosis Surveillance Data, please contact 
the RVCT/QA Training Team at 
rvctqualityassurance@cdc.gov. 
—Reported by DTBE’s RVCT QA Training Team: 
Lilia Manangan (lmanangan@cdc.gov), 
Elvin Magee (emagee@cdc.gov), 
and Cheryl Tryon (ctryon@cdc.gov) 
Division of TB Elimination 
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TB EDUCATION AND TRAINING 
NETWORK UPDATE 
 
TB ETN Webinar 
 
The TB Education and Training Network (TB 
ETN) was formed to bring together TB 
professionals to network, share resources, and 
build education and training skills. TB ETN 
membership includes representatives from TB 
programs, correctional facilities, hospitals, 
nursing homes, federal agencies, universities, 
the American Lung Association, Regional 
Training and Medical Consultation Centers, and 
other U.S. and international organizations 
interested in TB education and training issues. 
The TB ETN hosted its first webinar on June 20, 
2013, “Using Social Media to Expand the Reach 
and Effectiveness of Public Health.”  This 1-hour 
webinar was broadcast using Ready Talk 
software to 200 registered participants across the 
United States. The participants could submit 
questions using the “chat” function available 
through Ready Talk. 
 
The theme of social media and public health was 
chosen from topics submitted by TB ETN 
members and 2012 TB ETN Conference 
attendees. The invited speaker was Dr. 
Rosemary Thackeray, a professor in the 
Department of Health Science at Brigham Young 
University (BYU) in Provo, Utah. She has 
published several articles on social marketing 
and social media which have appeared in Health 
Promotion Practice, The American Journal of 
Health Promotion, Social Marketing Quarterly, 
and the Journal of Medical Internet Research. 
Before coming to BYU, Dr. Thackeray worked for 
the Utah Department of Health for 9 years. 
During a sabbatical from 2006 to 2007, she 
worked at CDC, in what was then the National 
Center for Health Marketing. 
 
The objectives of the webinar were that, by the 
end, participants could- 
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1. Describe at least four ways that social media 
has been be used to further public health 
work, 
2. List the five factors to consider when 
deciding whether to use social media as part 
of a public health program, and 
3. Explain at least two ways to apply social 
media to their own TB-related endeavors. 
 
Results of an evaluation immediately after the 
webinar indicate that a majority of participants 
rated the presentation positively: 
• 95% of respondents agreed or strongly 
agreed with the following statement:  The 
content of the webinar was relevant to the 
learning objectives.  
 
• 98% of respondents agreed or strongly 
agreed with the following statement: The 
speaker communicated the content 
effectively. 
 
• 92% of respondents agreed or strongly 
agreed with the following statement: If given 
an opportunity, I can apply knowledge 
gained as a result of this activity. 
 
A sample of feedback from webinar participants 
included the following: 
 
• “I’m a new user of social media and this 
webinar gave a very good overview of what's 
out there and its applicability. Short, but very 
much on point. Dr. Thackeray did a 
marvelous job!” 
• “The instructor was incredibly knowledgeable 
and interesting. She gave me more insight 
into social media and reinforced the need for 
me to become more engaged and apply 
these methods to TB activities where 
appropriate.” 
• “I thought that the inclusion of examples from 
a wide variety of fields, not just public health 
and more specifically TB, was useful.  It 
helps me to think creatively and evaluate 
strategies outside my field to see if I can 
borrow or adapt what others are doing.” 
• “I felt the speaker was excellent.  There was 
a lot of information, but it flowed very well 
and she kept me engaged throughout the 
presentation.” 
 
This webinar is archived and is available for 
viewing at  
Using Social Media to Expand the Reach and 
Effectiveness of Public Health Webinar. 
(https://cc.readytalk.com/cc/playback/Playback.d
o?id=7g2gjy). If you have any questions about 
TB ETN or about the webinar, you can e-mail 
Peri Hopkins at phopkins@cdc.gov or call 404-
639-8988.  
 
A second TB ETN webinar is being planned for 
November 2013. The webinar, “Best Practices for 
Training Using Technology,” is scheduled for 
November 7, 2013, from 1 pm until 2:30 pm EST.  
 
—Reported by Peri Hopkins, MPH 
Div of TB Elimination 
 
TB PROGRAM EVALUATION 
NETWORK UPDATE 
 
Evaluation of Sputum Culture 
Conversion in Illinois 
 
Background 
The Illinois Department of Public Health (IDPH) 
Tuberculosis (TB) Control Program serves 
Illinois, excluding the city of Chicago. The TB 
program is responsible for statewide TB 
surveillance, management of the Illinois TB case 
registry, and oversight of the TB prevention and 
control activities conducted by local programs. 
Local programs in Illinois are county or sub-
county programs that are independently funded 
and operated, and they provide direct TB 
prevention and control services within their 
jurisdictions.  
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A goal of the TB program is to ensure all patients 
are monitored for their response to treatment. 
One measure of response to treatment is 
documented conversion of a TB patient’s sputum 
culture. In 2009, the TB program noted that 
having incomplete or inaccurate data related to 
sputum culture conversion was a long-standing 
problem in Illinois, and it appeared the problem 
was worsening. The percentage of patients for 
whom we had documentation of culture 
conversion within 60 days had been decreasing 
steadily, from 57.5 percent in 2004 to 37.1 
percent in 2008. In addition, in 2008, Illinois 
implemented a new web-based surveillance 
system, which may have reduced the speed, 
completeness, and accuracy of reporting. 
 
Purpose 
The TB Program created an evaluation team in 
2009, which consisted of the IDPH TB nurse 
consultants, the IDPH TB surveillance 
coordinator, and the TB Nurse at the American 
Lung Association of Illinois (ALAI), to conduct a 
program evaluation to fully assess this issue. The 
evaluation project described here was the 
evaluation team’s first formal project. The 
purpose of this evaluation project was to improve 
patient outcome data by increasing the 
percentage of sputum culture–positive TB cases 
with documented culture conversion within 60 
days. This project included 1) analysis of data to 
determine the scope and nature of the problem 
and 2) exploration of strategies to improve the 
program’s performance on this indicator of the 
effectiveness of TB case management, to ensure 
response to treatment. The primary role of the 
ALAI nurse was to schedule and facilitate team 
meetings and assure that the team met its 
objectives and deadlines.   
 
Objectives 
The evaluation team set the following objectives:
1. By December 31, 2009, collect data, and by 
May 31, 2010, analyze data to identify the nature 
and scope of the problem and identify 
contributing factors and barriers. 
 
2. By August 30, 2010, the evaluation team will 
meet to review the data analysis, and identify and 
develop strategies to increase documentation of 
sputum culture conversion within 60 days of 
treatment initiation. 
 
3. Increase the percentage of sputum culture 
positive TB patients with documentation of 
sputum culture conversion within 60 days to 50 
percent by 2015 (national target 61.5 percent). 
 
Activities 
The surveillance coordinator developed a new 
electronic report, and the surveillance coordinator 
and the IDPH TB Nurse Consultant designated 
as the TB program evaluation focal point 
analyzed the data. The evaluation team revised 
the case review form to enhance data collection 
related to sputum conversion and to include the 
reason sputum conversion is not reported. 
Regional nurses reviewed reports and collected 
data from local programs; for new cases, nurses 
collected data during case reviews. 
 
The evaluation team held quarterly meetings via 
conference call. The team developed several 
strategies: 1) revising the case and cohort review 
tools, 2) emphasizing sputum culture conversion 
in case and cohort reviews, 3) consulting with 
local program staff, 4) providing education about 
sputum culture conversion at regional meetings, 
5) calling local program staff to collect data by 
telephone, 6) reminding local program staff to 
collect sputum and document culture conversion, 
and 7) monitoring surveillance data for 
completeness on an ongoing basis. 
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Sputum culture conversion data, by county 
County Sputum +  
Cases 
Convert 
≤ 60 days 
% Convert 
≤ 60 days 
1 2 1 50 
2 1 0 0 
3 4 4 100 
4 1 0 0 
5 1 0 0 
6 14 10 71.4 
7 1 1 100 
8 1 1 100 
9 6 4 66.7 
10 1 0 0 
11 1 0 0 
12 4 2 50 
13 1 1 100 
14 1 0 0 
15 1 0 0 
16 2 1 50 
17 1 1 100 
18 1 0 0 
19 1 0 0 
20 3 2 66.7 
21 1 0 0 
22 1 1 100 
23 1 1 100 
24 6 5 83.3 
25 1 1 100 
26 48 29 60.4 
Total 106 65 61.3 
 
Revised case review form – sputum culture conversion 
Case or cohort review form 
 
 
Results 
Original data from 2008 cases revealed that one 
third of patients had a sputum-culture conversion 
within 60 days, one third in more than 60 days, 
and one third lacked any documentation. 
Problems with accuracy of data included 
documentation of smear rather than culture 
conversion and use of laboratory result report 
dates rather than specimen collection dates. In 
general, counties with the largest numbers of 
cases and counties with TB clinics had better 
performance than counties with few cases and 
counties with all or most cases managed by 
private healthcare providers. 
 
After the TB nurse consultants provided 
education for local program staff and 
implemented the new strategies with case and 
cohort review, documentation of sputum culture 
conversion improved. 
 
Percent Sputum Culture Conversion in 60 Days 
Year Original 
Data 
Final 
Data 
National 
Target 
2008 37.1 50.2 61.5 
2009  61.3 61.5 
2010  67.4 61.5 
2011  66.2 61.5 
 
Local program staff reported better 
understanding of the reason for documenting 
sputum culture conversion. Counties with low 
incidence improved performance from 45 
percent to 75 percent in 2009. 
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Conclusion 
Absent, late, or incorrect documentation rather 
than poor clinical practice or inadequate case 
management was responsible for the low 
percentage of cases with sputum-culture 
conversion within 60 days. Owing to the 
increased focus on the reporting of sputum 
culture conversion results generated by the 
evaluation project, documented performance 
improved substantially. The activities were 
completed and the evaluation objectives were 
met and exceeded more quickly than originally 
anticipated. It was determined that further 
progress was unlikely, because of remaining 
barriers such as delayed sputum culture 
conversion in patients with extensive disease and 
limited capacity to enter data more quickly. After 
consultation with our CDC program and 
evaluation consultants, the IDPH TB Program 
decided to change its evaluation focus to a 
different performance area in 2011. 
 
For more information, contact Carrie Storrs at 
217-278-5928 or carrie.storrs@illinois.gov  
 
—Submitted by Carrie Storrs, RN, MPH, CPH 
Illinois Department of Public Health 
 
CLINICAL RESEARCH BRANCH 
UPDATE 
 
Results of TBESC Task Order 27: 
Health-System Benefits and Cost-
Effectiveness of Using 
Mycobacterium Tuberculosis Direct 
Nucleic Acid Amplification Testing to 
Diagnose Tuberculosis Disease in 
the United States 
 
Final results of the Tuberculosis Epidemiologic 
Studies Consortium’s Task Order 27 have been 
published in the journal Clinical Infectious 
Diseases.1 Investigators ascertained the health-
system benefits and cost-effectiveness of using 
the Mycobacterium Tuberculosis Direct (MTD) 
nucleic acid amplification test (NAAT) (Hologic 
Gen-Probe Incorporated, San Diego, CA) to 
diagnose TB disease. Participating sites included 
metropolitan Atlanta, Georgia; the states of 
Hawaii and Massachusetts; and four areas of 
Maryland. The sites represented the diverse 
patterns of TB diagnosis in the United States, 
with nearly all patients being hospitalized in 
Atlanta, a small portion being hospitalized in 
Hawaii, and mixed reliance on inpatient and 
outpatient diagnosis in Maryland and 
Massachusetts. The study’s results will help 
improve CDC guidelines for the NAAT and its 
efficient use, and they also will serve as a 
baseline for newer NAAT assays such as the 
Xpert MTB/RIF assay (Cepheid, Sunnyvale, 
California). 
 
In countries without uniform access to 
laboratories with capacity for mycobacteriology 
cultures, improvements in diagnosis of TB 
disease have been needed, because sputum-
smear microscopy for acid-fast bacilli detects 
less than half of TB cases.2 NAATs can provide 
results that inform diagnosis of pulmonary TB 
disease within 24–48 hours of submission to a 
laboratory for analysis. CDC recommended in 
1996 that NAAT be used on at least one 
respiratory specimen if the result of sputum-
smear microscopy is positive, for each patient 
being examined for pulmonary TB.3 The 
enhanced version of the MTD NAAT was 
approved by the Food and Drug Administration 
(FDA) in 1999, and CDC recommended its use in 
2009 on at least one (preferably the first) 
respiratory specimen (regardless of result from 
sputum-smear microscopy) of all patients 
suspected of pulmonary TB.4 However, anecdotal 
reports suggested that the use of NAATs was not 
widespread, for the presumed reason that it did 
not displace the need for any standard TB 
diagnostic tool and was technically demanding to 
perform. Moreover, individual providers and the 
directors of hospitals and laboratories determine 
whether to adopt NAAT, based on their own 
decision criteria. In addition, only one U.S. study 
has evaluated the cost-effectiveness of MTD 
NAAT, and only in a hospital setting. That study 
found the use of NAAT not cost-effective for 
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exclusion of TB in smear-positive patients who 
have suspected TB disease.5 A more 
representative, comprehensive study of 
programmatic benefits and cost-effectiveness 
was needed to show that NAAT usage could be 
advantageous. 
 
The purpose of Task Order 27 was to evaluate 
the MTD NAAT use, effectiveness, health-system 
benefits, and cost-effectiveness in the largest-
ever multisite cohort of patients with suspected 
pulmonary TB disease. Methods included data 
analysis from provider initial suspicion of TB 
disease (which we defined as the earliest of the 
following events: respiratory isolation, laboratory 
result with positive results from sputum-smear 
microscopy, TB treatment start, report of a 
suspected case of TB, or TB diagnosis) through 
final TB determination (TB confirmation or 
definitive exclusion). The multisite study 
consisted of retrospective reviews of inpatient 
and outpatient medical records of a cohort of 
2,140 patients suspected of having pulmonary 
TB reported to local jurisdictions during 2008–
2010.  
 
Of study patients, 40% had one or more 
specimens with positive results on sputum-smear 
microscopy and 60% had all specimens with 
negative results on microscopy. MTD NAAT was 
used for 43% of study patients, more for those 
with positive microscopy results (80%) than for 
those with negative results (19%). Thirty-seven 
percent of patients in the study had TB disease 
confirmed by culture isolation of M. tuberculosis, 
that is, 2.7 suspected cases per each confirmed 
case. Foreign-born patients were significantly 
more likely to have TB disease, but they were 
less likely to have had their specimens tested by 
NAAT when the sputum-smear microscopy 
results were negative. The study also found that 
public health laboratories (versus private 
laboratories) reported that they had protocols in 
place for use of MTD NAAT. 
 
Compared with no MTD NAAT use, study 
investigators found that use of MTD NAAT 
• Improved diagnostic accuracy (i.e., detected 
a higher proportion of true positives among 
all positives, true negatives among all 
negatives, and true positives among all those 
with TB) among all subpopulations of 
patients. It was also more specific (i.e., 
detected a higher proportion of true 
negatives among all those without TB), in all 
subpopulations except patients experiencing 
homelessness. 
 
• Reduced time to TB diagnosis for patients 
who had positive results from both sputum-
smear microscopy and MTD. 
 
• Reduced the number of medical procedures 
(biopsies, bronchoscopies, computed 
tomographies) and the usage of respiratory 
isolation for patients with positive smears 
and negative MTD results but without TB. 
 
• Resulted in an average 1.5 fewer months of 
unnecessary and potentially toxic TB 
medications in MTD-negative patients 
without TB. 
 
• Resulted in fewer contact investigations 
initiated for patients who had positive smears 
and negative MTD results, and who 
ultimately did not have TB. 
 
• Showed health system cost savings per 
additional patient who is HIV infected or 
homeless with TB diagnosed or excluded 
regardless of sputum-smear microscopy. 
Cost savings also occurred, per additional 
patient having a history of substance abuse 
with TB excluded and negative results on 
sputum-smear microscopy. 
 
MTD NAAT improved diagnostic accuracy and 
shortened turn-around time for an initial result, 
and it reduced unnecessary respiratory isolation, 
treatment, and contact investigations. In 
multivariable analysis, providers used MTD 
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NAAT results to significantly reduce time to 
confirm TB disease. 
 
In light of the experience from Task Order 27 and 
many other studies, using MTD NAAT is clearly 
more accurate6 than using sputum-smear 
microscopy as the determining factor in rapid TB 
disease diagnosis. In addition, Task Order 27 
provides data showing cost savings if NAAT is 
targeted to persons living with HIV, 
homelessness, or substance abuse (patients who 
are more likely to be hospitalized during TB 
evaluation.) 
 
The study serves as an incentive for providers 
and/or laboratories to adopt NAAT where it is not 
currently being used. The National Institutes of 
Health has recommended use of the NAAT for 
TB diagnosis in HIV-infected adults and 
adolescents with advanced immunodeficiency, 
because of their risk for rapid clinical progression 
to TB and risk of early death from TB, because 
NAAT has a high positive predictive value 
(proportion of true positives among all positives) 
for sputum specimens with positive smear 
microscopy results and acceptable sensitivity 
(proportion of true positives among al those with 
TB) for specimens with negative microscopy 
results.7 The Xpert MTB/RIF NAAT (which, 
compared to MTD NAAT, is less technically 
demanding, less prone to error, can concurrently 
diagnose potential multidrug-resistant TB, and is 
less expensive internationally) received FDA 
approval in July 2013. This will significantly 
contribute to prompt, accurate TB diagnosis, and 
it will possibly save lives. 
 
—Reported by Suzanne M. Marks, MPH, MA 
Div of TB Elimination 
Epidemiologist, Principal Investigator for TBESC 
Task Order 27 
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COMMUNICATIONS, 
EDUCATION, AND 
BEHAVIORAL STUDIES 
BRANCH UPDATE 
 
Celebrating 10 Years of Find TB 
Resources.org! 
 
Launched in October 2003 by CDC’s Division of 
Tuberculosis Elimination, the Find TB Resources 
website (www.findtbresources.org) is a one-stop 
site for finding and sharing TB resources. The 
website was created to offer a wealth of easily 
accessible CDC and non-CDC (domestic and 
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international) TB education and training 
resources for TB health care professionals 
including physicians, nurses, outreach workers, 
and health educators, in addition to providing 
access to materials for the general public.   
 
The Find TB Resources website has continued to 
grow and evolve since its creation.  After 
undergoing usability testing, a redesigned Find 
TB Resources Website was launched in 
September 2011. Some of the features of the 
redesigned website include a top navigation bar, 
additional search instructions, thumbnail images 
of materials, and an enhanced Research section 
that includes two new pages, the Translating 
Research into Practice (TRiP) page and the 
Program Evaluation Tools and Resources page. 
 
New materials and resources are constantly 
added to the website. It has more than 2,000 
resources in its database. Visitors to the website 
are invited to share their organization's TB-
related educational and training materials. 
Thanks to marketing efforts and the abundance 
of materials available on the website, Find TB 
Resources receives visitors from all around the 
world. In addition, the website continues to offer 
visitors information on submitting TB materials, 
tips for adapting materials, funding opportunities, 
TB organizations, TB mailing lists, and TB 
images. 
 
Each month, the Find TB Resources E-
Newsletter is sent to more than 3,800 
subscribers. This monthly newsletter informs 
readers about the featured Highlight of the 
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Month, additional helpful resources in the 
database, and other updates to the website. To 
subscribe to the E-newsletter, please visit 
www.findtbresources.org/newsletter.aspx. 
 
Please continue to visit and use the Find TB 
Resources Website! 
 
—Submitted by Allison Maiuri, MPH, CHES 
Division of Tuberculosis Elimination 
 
LABORATORY BRANCH 
UPDATES 
 
Julie Tans-Kersten Wins the 
NTCA 2013 Ed Desmond 
Laboratorian of the Year Award 
 
Julie Tans-Kersten, Advanced Microbiologist, 
State TB Laboratory Program Coordinator, 
Wisconsin State Laboratory of Hygiene, won the 
2013 National Tuberculosis Controllers 
Association (NTCA) Laboratorian of the Year 
Award. Julie was nominated by Lorna Will, RN, 
MA, Director, Respiratory and International 
Health Unit, in the Wisconsin Division of Public 
Health. Julie has been the Wisconsin Laboratory 
Tuberculosis Program Coordinator since 2004. 
 
Lorna writes of Julie in her nomination: “Julie 
never ceases to amaze me with her knowledge 
and professionalism. The population of 
Wisconsin has the extreme good fortune of 
having Julie as our Tuberculosis Program 
Coordinator at the State Laboratory of Hygiene. 
She is not only conscientious, efficient, and 
extremely knowledgeable, but she holds 
impeccable standards when it comes to her work 
in the laboratory, as well as with other 
professionals. Julie often acts as advisor and 
guide to not only laboratories around Wisconsin, 
but also throughout the country. She was one of 
the distinguished speakers at the 2011 NTCA 
conference in Atlanta. She is an invaluable asset 
to public health departments and clinicians 
throughout our state. 
 
“Julie often acts as an 
advocate for the State 
Tuberculosis Program as well 
as for the patients, by 
monitoring requests and 
testing results. She fosters 
the development of technical 
skills and provides crucial 
support and guidance to local 
laboratories within the state 
and to local health department staff by 
coordinating an annual training for local 
laboratories, public health partners, and 
healthcare providers. Her dedication alone is 
commendable. Julie often spends her nights and 
weekends working on projects that will better her 
department, her staff, and the Wisconsin 
Tuberculosis Program.” 
 
Dave Warshauer, Deputy Director, 
Communicable Disease Division at Wisconsin 
State Laboratory of Hygiene, provided this 
introduction to Julie’s award: “[Julie] has 
established a strong and respected relationship 
with our state TB Controllers and maintains a 
state TB laboratory network that provides quality 
laboratory services to the citizens of Wisconsin. 
The Wisconsin Mycobacteriology Laboratory 
Network is recognized as a model for the country 
under her leadership. Julie is recognized as a 
leader in the TB laboratory community by the 
Association of Public Health Laboratories (APHL) 
and has participated in many activities and 
projects that contributed to TB elimination efforts 
and the advancement quality laboratory services. 
She is dedicated to her work and constantly 
strives to improve our laboratory and TB control 
efforts. She’s a pleasure to work with and I 
congratulate her on accomplishments and on her 
recognition as winner of the Ed Desmond 
Award.” 
 
The DTBE Laboratory Branch congratulates Julie 
Tans-Kersten on this well-deserved honor! 
 
—Submitted by Frances Tyrrell, MPH, MT (ASCP), SM 
Div of TB Elimination 
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Unveiling the Mysteries of TB 
Laboratory Testing: 
A Laboratory Education Toolkit 
Designed for TB Field Staff 
 
The day-to-day business of TB control depends 
on the collection of specimens for laboratory 
testing and the reviewing of laboratory results. 
Programmatic decisions, like reporting a TB case 
to the state, prioritizing a contact investigation, or 
changing a patient’s TB medication regimen, use 
laboratory results as a guide. The importance of 
laboratory results is clear—but how many TB 
field staff (TB control workers in state and local 
TB control programs) truly understand the 
specific tests or prerequisites for producing these 
results?  
 
For the past year, staff from the City of Houston’s 
Bureau of TB Control and Public Health 
Laboratory have worked side by side to unveil 
the mysteries of the laboratory for field staff. TB 
control staff toured the TB laboratory with subject 
matter experts to get a start-to-finish overview of 
testing. The TB field staff met several times to 
take photos of laboratory equipment, such as the 
MGIT 960 or HPLC, and to further refine their 
understanding of sputum testing procedures. 
They consulted with state and local TB laboratory 
subject matter experts to learn about proper 
methods for collecting specimens in community 
settings outside of clinics, as well.   
 
As a result of their collaborative efforts, the team 
created a multiphase laboratory education toolkit. 
Recently presented at this year's National TB 
Conference, the first phase includes a number of 
handouts, which include 
• What You Need to Know About 
QuantiFERON-Gold (QFT), 
• What You Need to Know About Collecting 
Sputum, and 
• The series, What You Need to Know About 
Testing Sputum: 
o Acid-fast Bacilli (AFB) Direct Smear  
o Nucleic Acid Amplification Testing 
(NAAT)  
o Culture Media Inoculation  
o Growth Detection on Culture Media  
o Culture Identification  
o TB Drug Susceptibility Testing  
 
Each handout takes a comprehensive view of 
commonly collected specimens for TB testing. 
The material describes the specimen, the 
purpose of the test, tips to help collect a high-
quality specimen, and how it is processed in the 
laboratory. This straight-forward approach is 
designed with TB field staff in mind. The material 
reinforces the importance of quality specimen 
collection by explaining how the laboratory 
results assist in TB control program day-to-day 
functions, while providing insight into the 
laboratory's complex testing procedures.    
 
Currently, this team has begun work on the 
second phase of the toolkit. In this phase, they 
will develop a variety of visual media and lesson 
plans to accompany the handouts. These 
additional features will make it easier to 
incorporate the toolkit into formal group trainings. 
Local, state, and federal partners will be able to 
download the toolkit once the team launches its 
new website, as well. Be on the lookout for these 
new developments in 2014! 
 
By implementing this tool in your program's 
training, your TB field staff can gain a big-picture 
view of the procedures for specimen collection, in 
addition to understanding the rationale behind 
each test. TB field staff will be better prepared to 
collect high quality specimens. If you would like 
to receive more information about the laboratory 
education toolkit, please contact Nydia Palacios 
(nydia.palacios@houstontx.gov). Copies of the 
Phase One laboratory handouts are available 
upon e-mail request to Nydia.  
 
—Reported by Gregory R. Dufour, MPH, 
Microbiologist Supervisor;  
Nydia Palacios, Public Health Advisor, CDC/DTBE 
Houston Department of Health and Human Services 
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SURVEILLANCE, 
EPIDEMIOLOGY, AND 
OUTBREAK INVESTIGATIONS 
BRANCH UPDATES 
 
Developing a Surveillance Definition 
for Binational Tuberculosis Cases 
 
Background 
Successful treatment of persons with 
tuberculosis who cross international borders 
during their infectious or treatment periods 
requires significant collaborative efforts among 
TB programs in more than one country. 
Particularly with patients who go between the 
U.S. and Mexico, the relationship between border 
crossing and the impact on TB control in U.S. 
border states has been documented.1,2 TB 
patients who travel or move to another country 
require staff time and resources above and 
beyond what is typically provided for TB patients 
who receive all of their care and treatment in one 
country.2 However, owing to the lack of a 
uniformly applied surveillance definition for 
binational TB cases, there are currently no data 
that measure either the extent of the binational 
burden or the epidemiologic trends.   
 
In 1999, the Tuberculosis Along the U.S.-Mexico 
Border Work Group, made up of staff from CDC 
and 17 state and local programs in Arizona, 
California, New Mexico, and Texas, proposed a 
binational TB case definition and recommended 
development of a registry for binational TB 
cases.2 More recently, the U.S.-Mexico Binational 
Commission has developed a set of guidelines 
for cross-border coordination of public health 
events, such as infectious disease outbreaks, 
which includes a proposed general definition for 
a binational case that can be applied to all 
notifiable diseases.3 While these proposed 
definitions may be useful for programmatic 
purposes, they may not necessarily meet the 
needs of TB surveillance in the United States. 
 
Objective 
The objective of this project is to develop a TB-
specific surveillance definition that is easy to 
apply and interpret uniformly across reporting 
jurisdictions using routinely collected data that 
may or may not be currently reported to CDC. An 
effective and useful surveillance definition will be 
TB-specific as well as easy to apply and 
interpret, and will minimize inconvenience on TB 
programs by using information that is already 
being collected. In addition, the definition should 
be consistent with other binational definitions, 
and it should not detract from federal, state, or 
local TB control program activities. 
 
Summary of Recent Activities 
Estimating Binational TB Case Burden in Select 
Border Counties, California and Texas 
 
During October 2012–April 2013, epidemiologists 
from CDC’s DTBE interviewed key informants, 
including staff associated with binational 
treatment programs, at the state, regional, and 
county levels. They sought to describe systems 
of case management for binational cases and the 
collection and reporting of binational information. 
Data on binational patient characteristics were 
abstracted from medical or clinic records in four 
border counties to make an inventory of 
information currently being collected that could 
help in creating a standard surveillance definition 
for a binational TB case. Medical records for 
patients who met the following criteria were 
included in the review: 1) patient had a verified 
case of TB, 2) case was reported to the CDC 
National Tuberculosis Surveillance System in 
2011, and 3) patient was born in the United 
States or Mexico. 
 
Binational characteristics abstracted from the 
records included TB treatment in Mexico, contact 
investigation in Mexico, travel to Mexico during 
infectious period, travel to Mexico during 
treatment, contacts elicited in Mexico, and 
epidemiologically linked cases diagnosed in 
Mexico. This information was obtained from a 
combination of treatment forms, contact 
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investigation forms, patient interview forms, and 
case manager notes. Across all four counties, an 
average of 17% of TB cases that were reviewed 
either received treatment in Mexico or had a 
contact investigation done in Mexico, and 42% 
had at least one of the binational characteristics 
specified above. 
 
U.S.-Mexico Tuberculosis Summit 
DTBE staff held a half-day summit during the 
2013 National TB Conference. The purpose of 
the summit was to discuss key demographic, 
social, and risk factor data to be incorporated in a 
surveillance definition for a binational TB case. 
Invited speakers from federal, state, and local TB 
and border health programs presented their 
activities related to management and surveillance 
of binational TB cases and key data elements 
used to ascertain binational cases locally. 
 
In addition to DTBE staff, summit attendees 
included program staff from Arizona, California, 
New Mexico, and Texas, members of CDC’s 
Division of Global Migration and Quarantine, 
panel physicians (physicians who provide 
required medical examinations to persons 
applying for entry to the United States) from 
Mexico, and staff from Mexico’s National 
Tuberculosis Control Program. Attendees agreed 
that it is important to develop and pilot a 
surveillance definition for binational TB cases. 
 
Developing and Piloting a Surveillance Definition  
Data elements discussed during the NTCA U.S.-
Mexico TB Summit were summarized and used 
to create a draft surveillance definition for 
binational TB cases. A pilot project to implement 
the proposed definitions in at least six 
jurisdictions in areas along the U.S.-Mexico 
border, as well as at least one jurisdiction not 
located on the U.S.-Mexico border, is under 
development. Pilot sites will collect data on a 
standardized form and will send completed forms 
to CDC for data entry and analysis. An evaluation 
of the sensitivity and specificity of the proposed 
surveillance definition for binational TB cases will 
follow the pilot project. 
Conclusions  
There is a need for a national surveillance 
definition for binational TB cases in the United 
States that is TB-specific, easy to apply and 
interpret, and based on data that are already 
being routinely collected. The definition 
developed for surveillance purposes will not 
affect federal, state, or local TB control activities. 
The primary purpose of developing a surveillance 
definition is to quantify the burden and monitor 
trends in binational TB cases. Using the data to 
educate policy makers and partners in TB control 
will be helpful to promote investments in systems 
for prevention and control. For more information 
about the collaborative effort to develop a 
national surveillance definition for binational TB 
cases, please contact Rachel Yelk Woodruff by 
e-mail at zex5@cdc.gov or by telephone at 404-
639-6018. 
 
—Reported by Rachel Yelk Woodruff, Courtney Yuen, 
Mark Miner, Andy Heetderks, & Roque Miramontes 
Div of TB Elimination 
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PERSONNEL NOTES 
 
Deborah Bedell left DTBE earlier this year for a 
position as a Project Officer with CDC’s Division 
of Viral Hepatitis. In 1982 she began her public 
health career as a case manager with the 
Alabama Sexually Transmitted Disease (STD) 
program. In 1989, she joined CDC’s Division of 
STD/HIV Prevention (now the Division of STD 
Prevention) as a public health advisor (PHA) 
stationed in Alabama, and in 2003, she left CDC 
and returned to the Alabama STD program. In 
2008, Deborah returned to CDC and joined 
DTBE as a PHA assigned to the Florida TB 
control program in Tallahassee, Florida. Among 
her accomplishments there, she co-authored Mr. 
Tuber’s Coloring Book in collaboration with the 
Florida Bureau of TB and Refugee Health 
colleagues. This product was later adopted by 
the TB control program in Sidney, Australia, and 
by CDC’s TB Education and Training Network 
(TB ETN). She went on a 90-day temporary 
detail to help investigate a TB outbreak in a small 
rural town in Florida involving a family with more 
than four generations of TB disease. At the 2010 
Southeastern Regional TB Meeting, she 
presented findings from this investigation in 
“Addressing TB in African-American 
Communities: The Gadsden County Experience.” 
She won a 2009 CDC honor award for 
Excellence in Surveillance and Health Monitoring 
as part of the Decline in Reported TB Working 
Group, and later she was a co-author on the 
MMWR reporting an investigation of the 
decrease in reported TB. 
In August 2010, she accepted a DTBE 
assignment with the TB control program in South 
Carolina. Among her accomplishments there, she 
wrote South Carolina’s first Program Evaluation 
Plan. In 2011 she had a poster as well as an oral 
presentation, “Monitoring the Tuberculosis Case 
Evaluation Process for Immigrants and 
Refugees: The South Carolina Experience” at the 
TB Program Evaluation Network (TB PEN) 
meeting. She was selected to participate in a 
temporary duty assignment in Denver, Colorado, 
for the response to a high school TB outbreak, 
where she was involved in the cutting-edge use 
of TB’s new 12-dose drug treatment for latent TB 
infection. This contribution led to Deborah’s 
winning the February 2013 NCHHSTP Director’s 
Recognition Award along with Maria Galvis, who 
also assisted with the response. Deborah served 
as co-author on the MMWR article describing the 
Colorado outbreak and the successes achieved 
with the new treatment regimen.  
Deborah writes that, in her new position, she is 
able to apply the knowledge and experience 
acquired from DTBE. She credits DTBE with 
having a remarkable staff with unbelievably great 
support for their field staff. She gives special 
thanks to Dan Ruggiero and Gail Burns-Grant for 
the excellent job they did in preparing her for 
newer challenges, such as teaching her 
leadership skills that she states will always be an 
asset to her career with CDC. We thank Deborah 
for all her contributions to DTBE, and we wish 
her much luck in her new position! 
Emily Bloss, PhD, was the worthy recipient of the 
DTBE Director’s Quarterly Recognition Award for 
the Fourth Quarter of 2013. Emily was nominated 
for her work over the past 2 years with the World 
Health Organization (WHO) Global Task Force 
on Impact Measurement for outstanding 
international collaboration and leadership in 
strengthening national TB surveillance systems, 
leading and supporting the development of 
guidance documents and tools, and supporting 
prevalence surveys in multiple countries. 
 
Specifically, Emily has contributed to the 
development of international guidelines for 
national TB prevalence surveys and inventory 
studies for assessing underreporting, in which 
she helped define methods used for conducting 
these large studies. She also helped lead the 
development of internationally applied standards 
and benchmarks for TB surveillance. These 
WHO documents are used globally to measure 
impact of TB control strategies and strengthen 
national TB surveillance systems. With support 
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from others in DTBE, Emily is currently helping to 
develop a handbook that national TB program 
staff in high burden settings can use to more 
effectively analyze TB surveillance data. 
 
Emily has demonstrated exceptional skill in 
gaining the confidence and cooperation of 
partners through her 50% secondment with the 
Global TB Program at the World Health 
Organization. In this role, she has exceeded 
expectations by successfully and efficiently 
responding to the needs of both DTBE and WHO 
and facilitated collaboration and communication 
between the two organizations. Emily is 
commended for her leadership, innovation and 
collaboration in these areas. 
 
In addition to her work on the Task Force, Emily 
has continued to successfully work on a variety 
of complex and unique activities in IRPB and has 
proven to be versatile and innovative in her broad 
scope of work, which has spanned across 14 
different countries. For example, currently Emily 
is finishing up the fourth and final module of a 
USAID funded operations research course in 
Uganda where, despite consistent bureaucratic 
roadblocks, staff turn-over, and poor 
infrastructure, she has continued to maintain her 
sense of humor and cheerfulness when 
coordinating, teaching, and mentoring TB 
program staff as they learn to conduct their own 
epidemiologic studies. 
Zyrus Campbell has been helping DTBE as a 
webmaster. A native of Maryland, Zyrus earned 
his B.S. degree in 2001 from the University of 
Maryland, University College. He has worked as 
an independent consultant, developing websites 
for government agencies, small businesses, and 
nonprofit organizations; assessing Internet 
audiences for website usage; and creating Web 
graphics and other design elements. In addition 
to his IT interests, Zyrus also has an M.A. degree 
in religious studies from Howard University. 
Stephanie Chan, PhD, has joined DTBE and 
SEOIB as a Prevention Effectiveness Fellow and 
will be with us until 2015. During her time here, 
she will work on several cost-effectiveness 
projects related to screening options, outbreak 
investigations, and TB genotyping. Such 
analyses can help policymakers see more clearly 
the impact of TB prevention efforts and the trade-
offs of their decisions on how much and where to 
allocate resources. Prior to coming to CDC, 
Stephanie graduated from the Pardee RAND 
Graduate School with a degree in Policy 
Analysis; her dissertation project was titled 
“Fighting Obesity in the U.S. with State 
Legislation.” She also worked on a variety of 
health projects at the RAND Corporation in Santa 
Monica, CA, and managed the Medicaid budget 
for the New York City Office of Management and 
Budget. 
Allison DeFer has joined CEBSB and will be 
working with DTBE as a web developer. She 
received her Bachelor of Science degree in 
Information Systems Management from Auburn 
University. Prior to coming to CDC, Allison 
worked for Engauge, GE, MailChimp, and 
CareerBuilder in several capacities. She worked 
most recently with AutoTrader as an email 
developer. 
 
Alstead (Al) Forbes has left DTBE for a position 
with CDC’s Center for Global Health. His last day 
with DTBE was August 24. Al began his CDC 
career in February 1993 as a Public Health 
Associate with the New York City (NYC) 
Department of Health Bureau of Tuberculosis 
Control. In 1997, he was promoted and 
transferred to the New Jersey Department of 
Health and Senior Services Tuberculosis 
Program, where he served as the assistant to the 
DTBE senior PHA. In 1999, Al was selected as 
DTBE’s assistant project manager for the 
Tuberculosis Information Management System 
(TIMS) in Atlanta. In this position, he provided 
technical assistance and training to TIMS users 
nationwide. He worked closely with the 
Surveillance Branch regarding the interface of TB 
surveillance data and with the Field Services and 
Evaluation Branch (FSEB) program consultants 
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regarding resource needs and management 
problems. In 2001, he became a Program 
Consultant and assumed the duties of 
overseeing DTBE’s cooperative agreement 
activities and providing guidance and 
consultation to the Mid-Atlantic region. On 
September 18, 2005, he began serving in the 
Miami, Florida, PHA position, and returned to 
Atlanta in June 2007 as a TB Program 
Consultant. Since his return, he has provided 
guidance and program consultation not only to 
the Mid-Atlantic region but to the Pacific Island 
territories as well. A few highlights of other 
projects include the following: in 2009, as part of 
the RVCT Training Team, Al received the DTBE 
Director’s Recognition Award for development of 
updated training materials for the revised RVCT. 
In 2011, he was one of the recipients of an 
NCHHSTP group honor award for Excellence in 
Emergency Response (International) as part of 
the Haiti Responders Group. In addition, he was 
a co-author on an MMWR article that was one of 
the 2012 CDC World TB Day features, 
Tuberculosis Control Activities Before and After 
Hurricane Sandy — Northeast and Mid-Atlantic 
States, 2012. We will certainly miss Al, and we 
wish him all the best in his new position.  
 
Tom Kenyon, MD, MPH, is the Director of the 
Center for Global Health (CGH) at CDC. Dr. 
Kenyon most recently served as Country Director 
for CDC in Ethiopia from 2009 to 2013, where he 
played a major role in expanding partnerships 
with the Ethiopian Government in maternal child 
health, health systems strengthening, strategic 
information, TB, malaria, pandemic influenza, 
HIV prevention in key populations, and 
comprehensive HIV/AIDS care and treatment. 
 
His career with CDC began in 1994 as an 
Epidemic Intelligence Service Officer in the 
Division of Tuberculosis Elimination. From 1996 
to 2002, he served as the CDC Country Director 
in Botswana where he led numerous studies in 
HIV/TB and developed a wide range of initiatives 
in HIV/AIDS prevention with the Ministry of 
Health and partners from civil society. From 2002 
to 2006, Dr. Kenyon began CDC's operations in 
Namibia in partnership with the Ministry of Health 
where he led US Government efforts under the 
President's Emergency Plan for AIDS Relief 
(PEPFAR) to establish the national antiretroviral 
therapy (ART) program, prevention of mother-to-
child transmission (PMTCT), HIV surveillance, 
and comprehensive programs in HIV prevention 
and care. He returned to Washington, DC and 
served from 2006 to 2008 in the Office of the 
Global AIDS Coordinator, Department of State, 
as Principal Deputy Global AIDS Coordinator and 
Chief Medical Officer for PEPFAR. During his 
tenure as Principal Deputy, PEPFAR established 
systems of accountability, achieved major 
program expansion, and reached critical targets 
in HIV prevention, care, and treatment. 
 
Dr. Kenyon also previously served as 
Communicable Disease Director for the Chicago 
Department of Health and as a pediatrician and 
program director for Project HOPE in Grenada, 
West Indies, Swaziland, and Malawi. He 
graduated with a Bachelor of Science in Zoology 
from Indiana University and a Masters in Public 
Health with a focus on international health from 
the Johns Hopkins School of Hygiene and Public 
Health. He completed medical school at the 
University of Missouri-Columbia and 
subsequently completed a 3-year residency in 
pediatrics at the University of Arizona Health 
Sciences Center in Tucson. 
 
Katherine Klein, MPH, M(ASCP), has joined the 
Laboratory Capacity Team (LCT) of the 
Laboratory Branch as an Oak Ridge Institute for 
Science and Education (ORISE) fellow. Kate will 
be assisting LCT and the Global Laboratory 
Activity (GLA) with providing consultation and 
technical assistance to TB laboratories and TB 
programs in the United States and overseas. She 
will assist with educational activities, such as 
workshops on the laboratory diagnosis of TB, 
and she will design and manage a project to build 
laboratory capacity in TB high-priority countries. 
Kate earned her BS in Microbiology and BA in 
Physiology from the University of Minnesota in 
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2005. From 2005 to 2011 she worked in the 
Mycology/Mycobacteriology laboratory at the 
Mayo Clinic in Rochester, MN, first as a bench 
technologist and then as a Quality Specialist. 
She became certified in clinical microbiology 
through ASCP in 2008. While at Mayo, Kate 
volunteered with the Minnesota Interlaboratory 
Microbiology Association, the Rochester Healthy 
Communities Partnership, United Way, and the 
Rochester World TB Day group. In May, Kate 
graduated with an MPH degree in Hospital and 
Molecular Epidemiology and a Certificate in 
Global Health from the University of Michigan in 
Ann Arbor, MI. While at the University of 
Michigan, she volunteered with the Blue 
Mountain Project in Hagley Gap, Jamaica, and 
completed an internship with the TB program at 
the Michigan Department of Community Health 
(MDCH). During her internship at MDCH, Kate 
participated in education and outreach activities 
and in analyzing demographic and clinical 
characteristics of TB cases in Michigan.  
 
Margaret Patterson has left DTBE for a position 
as a Project Officer with CDC’s Division of Viral 
Hepatitis. Margaret joined CDC in 2001 and was 
assigned to the Washington, DC, STD Program. 
At that time, she already had several years of 
public health experience, working mostly in the 
South Carolina STD Program. In April 2003, she 
joined the DTBE Field Services Branch as a 
Public Health Advisor (PHA) assigned to the 
West Palm Beach, Florida, TB Program. In 2004, 
she accepted a DTBE assignment with the South 
Carolina TB control program, and in 2009, she 
transferred to the Kentucky TB control program.  
As the Assistant TB Program Manager and CDC 
liaison to the Commonwealth of Kentucky, 
Margaret facilitated the local health department 
response to TB outbreaks. In one instance, she 
assisted DTBE’s Outbreak Investigations Team 
with a unique TB genotype cluster occurring in 
six communities, while simultaneously assisting 
with a CDC epidemiological technical assist 
assignment involving correctional facilities and 
homeless shelters in the Louisville area. Working 
with the Southeastern National Tuberculosis 
Center, she served as one of the Lead PHAs on 
the pilot for DTBE’s Enhanced Contact 
Investigation Course. She organized Kentucky’s 
first Cohort Review, and she developed 
Kentucky’s first quality assurance and 
improvement review tool. She coordinated 
multiple testing and screening activities within the 
homeless shelters in Louisville, and she 
submitted an abstract of these activities entitled, 
“Investigation of Mycobacterium Tuberculosis 
genotype cluster: PCR-2118_KY011 Louisville 
Metro County Health Department, 2000-2009.” 
This was presented as a poster at the 2010 
National Tuberculosis Conference and won first 
place. 
In South Carolina, Margaret collaborated with the 
University of South Carolina’s Institutes for 
Family Services to address TB in the African 
American Community, serving as Project Director 
of the CDC demonstration project, “Intensification 
of TB Prevention, Control and Elimination 
Activities in African American Communities in the 
Southeastern United States.” She contributed to 
the report, “Understanding the Social and 
Cultural Determinants of Tuberculosis: African 
Americans and Tuberculosis in South Carolina,” 
which revealed TB rates among persons of racial 
or ethnic minorities were 5 to 10 times higher 
those among white persons in the same region. 
At the 38th World Conference on Lung Health, 
Cape Town, South Africa, she served as co-
author for an abstract and poster presentation 
entitled, “Tuberculosis PhotoVoice: Mobilization 
and Empowerment in the Communities” for four 
PhotoVoice sites: El Paso, TX; Chiang Mai, 
Thailand; Rio de Janeiro, Brazil; and South 
Carolina. She also represented both CDC and 
South Carolina on a panel at that meeting. 
In addition, she served as evaluation coach as 
part of TB ESC’S Task Order 15: Enhancing 
Tuberculosis Programs’ Capacity for Evaluation: 
Testing New Tools and Developing an Evaluation 
Toolkit, a project that responded directly to 
CDC’s and DTBE’s commitment to facilitating the 
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self-evaluation of TB programs. She also had a 
temporary duty assignment in New Orleans, LA, 
helping with the Hurricane Katrina Disaster Relief 
efforts for CDC. We thank Margaret for her many 
contributions to TB control over the past 10 
years, and we wish her all the best in her new 
position! 
Brandy Peterson, MPH, MCHES, has left DTBE 
and has joined the Division of STD Prevention, 
Health Systems Research and Evaluation 
Branch, Program Evaluation Team, as of August 
26. Beginning January 3, 2010, Brandy worked 
for the Program Evaluation Team in DTBE’s Field 
Services and Evaluation Branch (FSEB) as a 
Health Scientist. During her tenure with the FSEB 
Program Evaluation Team, Brandy did an 
exceptional job of coordinating the TB Program 
Evaluation Network (TB PEN) Steering 
Committee, assisting program evaluation 
capacity building for TB PEN focal points (state 
and local staff serving as points of contact for TB 
PEN). Brandy convened the TB PEN conference 
planning committee and worked with the TB ETN 
in organizing and successfully implementing the 
annual TB Education, Training, and Evaluation 
Conference. She provided technical assistance 
and guidance to public health officials in 25 TB 
programs in planning and implementing 
evaluation activities. Brandy oversaw the 
collection and management of data for the 
Aggregate Reports for TB Program Evaluation 
(ARPEs) and served as a project officer for this 
project. She took part in an evaluation project in 
SEOIB in collaboration with Dr. Brian Baker. She 
also worked with IRPB colleagues on an 
evaluation of TB/HIV collaborative activities in 
Guyana, leading the qualitative assessment with 
more than 50 interviews of clinic staff and 
patients. Brandy’s many contributions are greatly 
appreciated. Her work ethic, dependability, and 
collaborative spirit made her an irreplaceable 
asset to FSEB. Brandy will be missed, and we 
wish her the best as she begins her new position 
in the STD program. 
 
Erik Reaves, DO, is one of the new EIS officers 
who joined DTBE this year. He has joined the 
SEOIB Outbreak Investigations and Molecular 
Epidemiology Activity teams. Erik is a Preventive 
Medicine Officer, having served most recently as 
Deputy Director of the Department of Emerging 
Infections at the Naval Medical Research Unit 6 
in Lima, Peru. He is board certified in preventive 
medicine. Erik earned his undergraduate degree 
in Biological Sciences from Ohio University and 
was commissioned in the U.S. Navy. He earned 
his medical degree from Ohio University College 
of Osteopathic Medicine in 2003 and began his 
active duty naval career. Erik completed his 
postgraduate internship medical training at the 
Naval Medical Center in San Diego, California, in 
2004 and medical residency training in August 
2008. From September 2008 to June 2010, Erik 
served as a Preventive Medicine Officer and 
medical epidemiologist at the Navy 
Environmental and Preventive Medicine Unit 6 in 
Pearl Harbor, Hawaii. He led disease 
surveillance activities for the U.S. Pacific 
Command Navy and Marine Corps operational 
forces and provided medical care in the travel 
and preventive medicine clinic at the Naval 
Health Clinic in Hawaii. 
 
Aditya Sharma, MD, is one of the new EIS 
officers in DTBE this year; he has joined the 
International Research and Programs Branch. 
Aditya completed his undergraduate studies at 
the University of Delaware, medical school at 
Yale University, and residency training in family 
medicine at Contra Costa (CA) Regional Medical 
Center. During his medical school education, he 
wrote a thesis on the cost-effectiveness of 
Hepatitis A and B vaccination in jail inmates. 
Aditya is board certified in family medicine. He 
became interested in public health while serving 
as a physician in volunteer positions in Nepal and 
South Sudan. After completing an internship in 
emergency medicine, he volunteered with Nyaya 
Health; in this position, he worked with a group of 
physicians and epidemiologists in the U.S. and in 
the remote district of Achham in Nepal to help 
develop sustainable health care services for a 
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population of 250,000. In addition, after 
completing a residency in family medicine, he 
worked as a medical doctor in South Sudan with 
Doctors without Borders. 
 
Tyson Volkmann, PhD, MPH, is one of the new 
EIS officers in DTBE and has joined the 
International Research and Programs Branch. 
Tyson recently completed his doctoral work at 
the University of California, San Diego, and San 
Diego State University, researching substance 
use and HIV prevention. As an NIH-supported 
Pre-Doctoral Fellow during 2009-2012, he 
worked in the U.S.-Mexico border region, 
focusing on populations at high risk for 
transmission of HIV and TB, such as injection 
drug users, female sex workers and their male 
clients, and migrants. He is currently a Fellow in 
the Interdisciplinary Research Training Institute, 
which is supported by the National Hispanic 
Science Network on Drug Abuse at the University 
of Southern California. Tyson’s global public 
health experiences include projects in Mexico, 
Ethiopia, and Brazil. He holds an MPH degree 
from the University of Alabama, Birmingham, 
where he worked in public health preparedness 
for several years. 
 
Jonathan Wortham, MD, Lieutenant Commander, 
U.S. Public Health Service, has joined the 
Outbreak Investigations Team of SEOIB, DTBE. 
Jonathan joined CDC in 2011 as an Epidemic 
Intelligence Service (EIS) Officer with the 
Respiratory Diseases Branch in the National 
Center for Immunization and Respiratory 
Diseases. There, he led several Legionella 
outbreak investigations and performed analyses 
of both racial disparities in invasive 
pneumococcal disease and antibiotic prescribing 
for community-acquired pneumonia. Jonathan 
completed medical school and residency at 
Baylor College of Medicine and is board certified 
in pediatrics. Having a strong interest in field 
work and analytic investigations, Jonathan is 
excited about his new role in DTBE. 
 
CALENDAR OF EVENTS 
 
October 30–November 3, 2013 
44th UNION World Conference on Lung Health 
Paris, France 
The Union 
 
November 2–6, 2013 
141st APHA Annual Meeting 
Boston, MA 
American Public Health Association 
 
December 2–6, 2013 
Pacific Island TB Controllers Association (PITCA) 
Meeting 
Honolulu, HI 
 
December 3, 2013 
Advisory Council for the Elimination of 
Tuberculosis (ACET) Webinar 
Atlanta, GA 
Margie Scott-Cseh 
